- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04020289
A Psychoeducational Program "BalancingMySwing" for Patients With Bipolar Disorder
A Randomized Controlled Trial of a Psychoeducational Program"BalancingMySwing" for Patients With Bipolar Disorder
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The psychoeducation BalancingMySwing (BMS) program has been developed manually and its feasibility has been tested in our previous study. This 3-year research project aimed to further examine the immediate and lasted effects of BMS program for bipolar disorders (BD), and to assess its knowledge dissemination and the transferability of its evidence-based practice across multiple sites.
During the first 2 years, a randomized controlled trial was conducted. Patients diagnosed with BD were recruited and 104 patients were randomly assigned to treatment as usual (TAU) or to 8 BMS sessions. A battery of three outcome indicators-social rhythm, illness perception, and symptom severity-were used to examine the effects of the two groups at baseline, after intervention, and every 3 months until half year. In addition, a pre- and post-test quasi-experimental study combined with qualitative design was used to assess the translational feasibility of BMS and to explore related barriers and facilitators of implementing BMS in clinical settings in the third year. Nurses from 4 Hospitals received the BMS training, and patients with BD received the BMS translated in practice were recruited.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Had a DSM-IV(Diagnostic and Statistical Manual of Mental Disorders-IV) diagnosis of BP-I or II confirmed through the interviews using the Chinese version of the Modified Schedule of Affective Disorder and Schizophrenia-Lifetime.
- Able to speak and read Taiwanese or Taiwanese Mandarin Chinese
- Had signed a written consent form
- Agreed to accept the following medication therapy during the study: a mood stabilizer (valproic acid or lithium salts), an antidepressant, second generation antipsychotics, anxiolytics (lorazepam [< 8 mg/day]), and medicine to counteract side effects: extrapyramidal symptoms, tachycardia, and involuntary movement of smooth muscles in the gastrointestinal tract, urinary tract, lungs, etc.
Exclusion Criteria:
- Required immediate hospitalization
- Had any comorbidity with substance abuse or were current alcohol or drug abusers, or had been in the previous year
- Had been diagnosed with an organic psychosis, a neurodegenerative disease, a personality disorder, or impaired cognitive abilities
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: "BalancingMySwing"
Psychoeducational Program "BalancingMySwing" for bipolar disorder
|
Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing" group psychotherapy
|
Ander: treatment as usual (TAU)
Patients received treatment as usual
|
Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing" group psychotherapy
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Changes from Baseline Social Rhythm through Study Completion, at the 3rd and the 6th month after study completion
Tijdsspanne: At baseline; through study completion, an average of 2 months; at the 3rd and the 6th month after study completion
|
Social Rhythm Metric-5 items (SRM-5)-- The total scores range from 0 to 5; the higher the score the more regularly the activities occur.
|
At baseline; through study completion, an average of 2 months; at the 3rd and the 6th month after study completion
|
Changes from Baseline Illness Perception through Study Completion, at the 3rd and the 6th month after study completion
Tijdsspanne: At baseline; through study completion, an average of 2 months; at the 3rd and the 6th month after study completion
|
Illness Perception Questionnaire-Revised (IPQ-R) has 3 subscales.
The first subscale (identity) determines whether patients attribute specific symptoms to BD (total score: range = 0-10).
The second subscale assesses 25 items of illness perceptions.
The third subscale assessed the causes of BD.
The second and third subscales are rated on a 5-point Likert scale (range: 1~5).
A higher score on each item indicates a stronger belief in that illness perception.
|
At baseline; through study completion, an average of 2 months; at the 3rd and the 6th month after study completion
|
Changes from Baseline Manic Symptom through Study Completion, at the 3rd and the 6th month after study completion
Tijdsspanne: At baseline; through study completion, an average of 2 months; at the 3rd and the 6th month after study completion
|
Young Mania Rating Scale (YMRS)--The total score of the 11-item YMRS is the summation of the 2 subscales (range: 0-60), and could be divided into four levels: 0 to 12 means remission, 13 to 19 means minimal severe, > 20 as diagnosed with mania based on DSM-IV(Diagnostic and Statistical Manual of Mental Disorders, IV) criteria, and over 25 showed obvious symptoms.
|
At baseline; through study completion, an average of 2 months; at the 3rd and the 6th month after study completion
|
Changes from Baseline Depressive Symptom through Study Completion, at the 3rd and the 6th month after study completion
Tijdsspanne: At baseline; through study completion, an average of 2 months; at the 3rd and the 6th month after study completion
|
Hamilton Depression Rating Scale (HDRS)--The total score of the 17-item HDRS is the summation of the 2 subscales(ranged: 0- 52), and could be divided into four levels: 0-7 means remission, 8-13 means mild severe, 14-22 means moderate severe, and > 23 means very severe.
|
At baseline; through study completion, an average of 2 months; at the 3rd and the 6th month after study completion
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Esther C Lin, National Cheng Kung University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NCKU
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ANALYTIC_CODE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Bipolaire stoornis
-
University of HoustonOnbekend
-
New York City Health and Hospitals CorporationBeëindigdGlaucoom | Ziekte van het netvlies | Visuele Pathway DisorderVerenigde Staten
-
Neuro-Eye Diagnostic Systems, LLCNeuro-ophthalmology of Texas PLLCAanmelden op uitnodigingMacula ziekte | Visuele Pathway Disorder | Ziekte van de oogzenuwVerenigde Staten
-
Fondazione G.B. Bietti, IRCCSVoltooidGlaucoom | Optische neuropathie, ischemische | Optische zenuw | Visuele Pathway Disorder | Neurale geleidingItalië
-
University of MiamiNational Eye Institute (NEI)VoltooidGlaucoom | Maculaire degeneratie | Retinale degeneratie | Optische neuropathie | DrDeramus verdachte | Visuele Pathway DisorderVerenigde Staten
-
Isfahan University of Medical SciencesVoltooidZiekte van Tanger | Body Mass Index Quantitative Trait Locus 5 DisorderIran, Islamitische Republiek
-
Weill Medical College of Cornell UniversityUniversity of California, Los Angeles; University of Wisconsin, MilwaukeeVoltooidTourette syndroom | De stoornis van Gilles de la Tourette | Gilles de la Tourette | Gilles de la Tourette-syndroom | Ziekte van Gilles de la Tourette | Tourette-ziekte | Tic Disorder, Gecombineerde Vocale en Multiple Motor | Meerdere motorische en vocale ticstoornis, gecombineerd | Ziekte van Gilles... en andere voorwaarden
Klinische onderzoeken op Psychoeducational Program "BalancingMySwing"
-
Cefaly TechnologyVoltooidMigraineVerenigde Staten
-
IWK Health CentreCanadian Institutes of Health Research (CIHR)Voltooid
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Nog niet aan het wervenOuderschap | Interventie ouderschapVerenigde Staten
-
Tai Po HospitalVoltooid
-
McMaster UniversityActief, niet wervendSuikerziekte | Meerdere chronische aandoeningenCanada
-
Columbia UniversityWorld Bank; United NationsVoltooid
-
National Healthcare Group, SingaporeTan Tock Seng HospitalVoltooidDiabetespatiënten, gamification, diabeteseducatieSingapore
-
Ullevaal University HospitalUniversity of Oslo; The Royal Norwegian Ministry of Health; Regionsenter for barn... en andere medewerkersOnbekend
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)VoltooidObesitas | Cardiovasculaire risicofactor | Diabetes Mellitus-risico
-
Cefaly TechnologyVoltooid